Yo tomo un primo hermano de los medicamentos prohibidos y esto es lo que he encontrado en el uptodate.
Yo por suerte no lo uso mucho 
De todas formas... creo que me voy a pasar a otros tratamiento a ver qué tal me va :p
However, no definite causal relationship has been established [48], and two case-control studies did not detect an increased risk of lymphoma among patients treated with topical calcineurin inhibitors [49,50]. The Pediatric Eczema Elective Registry (PEER) is an industry-sponsored, ongoing cohort study established in 2004 as part of the post-marketing commitments for the approval of pimecrolimus to evaluate the risk of malignancy in children. Among 7500 children enrolled between 2004 and 2014, five malignancies (two leukemias, one osteosarcoma, and two lymphomas) were reported [51]. The standardized incidence ratio (SIR) based upon the age-standardized Surveillance, Epidemiology, and End Results Program population was 1.2 (95% CI 0.5-2.8) for all malignancies, 2.9 (95% CI 0.7-11.7) for lymphoma and 2.0 (95% CI 0.5-8.2) for leukemia. Although the excess risk of lymphoma and leukemia is not statistically significant, the authors acknowledge that the small sample size and the resulting wide confidence interval may not allow to exclude all risk.
A subsequent meta-analysis [52] did not find a statistically significant association between the use of topical calcineurin inhibitors and risk of lymphoma, although an included cohort study reported a fivefold increased risk of T cell lymphoma in patients exposed to topical tacrolimus (relative risk 5.44, 95% CI 2.51-11.79) [53].
Waiting for more reassuring data from larger studies, the following FDA recommendations seem reasonable precautions:
●Use these agents only as second-line therapy in patients unresponsive to or intolerant of other treatments.
●Avoid the use of these agents in children younger than two years of age; clinical studies have found higher rates of upper respiratory infections in children younger than two years who were treated with pimecrolimus.
●Use these agents only for short periods of time and use the minimum amount necessary to control symptoms; avoid continuous use.
●Avoid the use of these agents in patients with compromised immune systems.
Providers and patients will need to weigh the risks and benefits of topical calcineurin inhibitors in comparison to those of other therapies. In particular, calcineurin inhibitors may continue to have an important role in the management of atopic dermatitis in areas at high risk for skin atrophy when treated with corticosteroids (eg, face)
